Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome

Wallert, Elon; Letort, Erwann; van der Zant, Friso; Winogrodzka, Ania; Berendse, Henk; Beudel, Martijn; de Bie, Rob; Booij, Jan; Raijmakers, Pieter; van de Giessen, Elsmarieke

doi:10.1186/s13550-022-00943-6

EJNMMI Research

Table 1 Case overview with clinical and imaging information

From: Comparison of [¹⁸F]-FDOPA PET and [¹²³I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome

	Symptoms	Hoehn and Yahr	Age	Disease duration in years	History of psychiatric or neurologic disorders	Result FDOPA-PET Reported uptake	Result DAT-SPECT Reported binding	FDOPA-PET				DAT-SPECT				Months between scans	Final diagnosis
	Symptoms	Hoehn and Yahr	Age	Disease duration in years	History of psychiatric or neurologic disorders	Result FDOPA-PET Reported uptake	Result DAT-SPECT Reported binding	CR	CL	PR	PL	CR	CL	PR	PL	Months between scans	Final diagnosis
Patient 1¹	Restless while sleeping, dysarthria, weakness, cognitive symptoms	N/A	68	0.75	–	Normal	Severely reduced	2.47	2.56	2.29	2.33	1.58	1.47	1.82	1.78	2	Possible MSA-P
Patient 2¹	Walking disorder, tremor, bradykinesia, rigidity	3	51	3	–	Slightly reduced	Severely reduced	1.59	1.70	1.69	1.67	2.26	2.13	1.88	1.83	3	PD
Patient 3¹	tremor	2	66	1	Epilepsy	Normal	Reduced	2.08	2.12	2.11	2.06	2.46	2.44	1.99	1.88	< 1	PD
Patient 4²	Pain, mild rigidity, tremor	N/A	65	0.75	–	Normal	Normal	2.35	2.59	2.96	2.93	3.45	3.4	3.33	3.24	7	Inconclusive
Patient 5²	Urine incontinence, walking disorder, dysarthria, bradykinesia, rigidity	N/A	60	8	–	Normal	Reduced	2.43	2.46	2.71	2.49	2.2	1.9	2	1.9	11	Probable MSA-P
Patient 6²	Walking disorder, tremor, rigidity	3	70	3	Epilepsy	Normal	Severely reduced	2.37	2.49	2.25	2.33	2.5	2.6	1.6	1.8	7	PD
Patient 7²	Walking disorder, bradykinesia	3	77	3.5	vitamin B12 deficiency	Normal	Reduced	1.99	2.52	2.38	2.35	2.5	2.0	1.9	2.1	6	PD
Patient 8²	Walking disorder, dysarthria, mask expression, bradyphrenia, bradykinesia,	N/A	69	0.7	–	Normal	Normal	2.57	2.68	2.98	2.86	2.97	2.87	2.62	2.45	3	Inconclusive (passed away)
Patient 9³	tremor	2	76	1	transient bilateral ptosis (side effect)	Asymmetric slightly reduced	Reduced	2.10	2.20	2.37	2.29	2.47	2.37	2.28	2.03	9	PD
Patient 10³	Tremor, mask expression	1	67	2	–	Normal	Reduced	2.92	2.89	2.50	2.52	1.69	1.68	1.31	1.16	15	PD
Patient 11²	Tremor, bradykinesia, mask expression	2	65	1	–	Normal	Severely reduced	2.55	2.61	2.11	2.03	1.9	1.7	1.5	1.4	7	PD

1 = DAT-SPECT performed at Northwest Clinics, 2 = DAT-SPECT performed at Amsterdam UMC, location Vrije Universiteit, 3 = DAT-SPECT performed at Amsterdam UMC, location University of Amsterdam, CR = right caudate nucleus-to-occipital cortex ratio, CL = left caudate nucleus-to-occipital cortex ratio, PR = right putamen-to-occipital cortex ratio, PL = left putamen-to-occipital cortex ratio

Back to article page